Markets
MDT

Medtronic Unveils Favorable CoreValveEvolut R Study Results

An image of stock prices rising and declining in value
Credit: Shutterstock photo

Medical device major Medtronic plcMDT recently received favorable one-year data for its renowned transcatheter aortic valve replacement (TAVR) using the CoreValveEvolut R System. The Evolut R CE trial was based on 60 patients across the U.K., Australia and New Zealand, who are at high and extreme risk for open heart surgical aortic valve replacement.

The study, presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, confirmed exceptional procedural outcomes in the said category of patients with Evolut R through one year. The one-year stroke rate was also found to be low at 3.4%. According to the company, Evolut R CE validates more improved TAVR outcomes for patients when using Medtronic's CoreValveEvolut R.

The data also showed strong hemodynamic performance which according to Medtronic, is owing to the valve's supra-annular design. It also showed no incidents of valve dysfunction, procedural death, annular rupture, coronary occlusion, valve thrombosis, embolization or conversion to surgery.

Evolut R valve is delivered through the EnVeo R Delivery Catheter System, which features an InLine Sheath that significantly reduces the profile size to the lowest available in the market. According to Medtronic, a smaller profile size provides a greater opportunity to treat patients with smaller vessels and may minimize the risk of major vascular complications, in some patients.

With such exceptional results, Medtronic strongly affirms CoreValve Evolut R as the TAVR platform of the future. Buoyed by the progress, an increased number of physicians are expected to gradually accept CoreValve as a more suitable alternative for TAVR in high and extreme-risk surgery patients. We believe this positive news will help Medtronic capture a larger share in the global TAVR market, which is expected to grow 20% to 25% annually. This, in turn, will mean greater returns for the company's shareholders.

Currently, the stock carries a Zacks Rank #3 (Hold). Some better-ranked medical products stocks are Baxter International Inc. BAX , Hill-Rom Holdings, Inc. HRC and NuVasive, Inc. NUVA . All the three stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MEDTRONIC (MDT): Free Stock Analysis Report

BAXTER INTL (BAX): Free Stock Analysis Report

NUVASIVE INC (NUVA): Free Stock Analysis Report

HILL-ROM HLDGS (HRC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MDT NUVA BAX

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More